TY - JOUR AU - Favaloro, Emmanuel J. TI - Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease SN - 0340-6245 SN - 2567-689X PY - 2010 JO - Thromb Haemost JF - Thrombosis and Haemostasis LA - EN VL - 104 IS - 11 SP - 1009 EP - 1021 DA - 2017/11/24 KW - von Willebrand factor KW - VWF KW - collagen binding KW - von Willebrand disease KW - VWD KW - diagnosis AB - This study reports on the evaluation of seven commercial von Wille-brand factor (VWF) collagen binding (VWF:CB) assays to potentially assist the discrimination of types 1 and 2 von Willebrand disease (VWD). Samples from 25 patients with type 1 VWD, of varying severity, were co-tested with 16 samples from patients with types 2A or 2B VWD, plus various control samples, using each commercial VWF:CB assay assessed against our standard (reference) in-house VWF:CB assay, as well as our in-house VWF antigen (VWF:Ag) and ristocetin cofactor (VWF:RCo) assays. Commercial VWF:CB assays varied in their ability to discriminate types 1 and 2A/2B VWD. The optimal VWF:CB/VWF:Ag ratio at which optimal discrimination occurred also differed between assays, with some improvements observed with some (but not all) as-says following a harmonisation process that aimed to correct for different calibrator effects. Assay variability also compromised assay utility in some test occasions. Future standardisation and improvements in some commercial VWF:CB assays are needed before the VWF:CB assay can be more fully and globally utilised for discrimination of VWD types in diagnostic laboratories. PB - Schattauer GmbH DO - 10.1160/TH10-06-0360 UR - http://www.thieme-connect.de/products/ejournals/abstract/10.1160/TH10-06-0360 ER -